Concepedia

Wesley Blackaby

WB

Statistics

Publications

19

Citations

2K

H-Index

15

Active since

2005

Affiliations

MSD (UK) Limited (United Kingdom)(Current)

CHDI Foundation

Charles River Laboratories (United Kingdom)

The Gurdon Institute

University of Cambridge

Wesley Blackaby is an author at MSD (UK) Limited (United Kingdom) specializing in pharmacology, medicine, and drug discovery.

ORCID

Top concepts

Publications per year

2005–2023

19

Publications

19

Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia

Eliza Yankova, Wesley Blackaby, Mark R. Albertella et al. · Nature · 2021 · 1.2K citations · Full text

, , +9

Targeting the m<sup>6</sup>A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication

Hannah M. Burgess, Daniel P. Depledge, Letitia Thompson et al. · Genes & Development · 2021 · 137 citations · Full text

Imidazo[1,2<i>-a</i>]pyrimidines as Functionally Selective and Orally Bioavailable GABA<sub>A</sub>α2/α3 Binding Site Agonists for the Treatment of Anxiety Disorders

Simon Goodacre, Leslie J. Street, David J. Hallett et al. · Journal of Medicinal Chemistry · 2005 · 132 citations · Full text

, , +19

Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity

Andrew A. Guirguis, Yaara Ofir-Rosenfeld, Kathy Knezevic et al. · Cancer Discovery · 2023 · 100 citations

Imidazo[1,2-a]pyrimidines as functionally selective GABAA ligands

Wesley Blackaby, John Atack, Frances A. Bromidge et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 41 citations · Full text

, , +3

1–5 of 19